Farringdon Capital’s AbbVie ABBV Stock Holding History

Farringdon Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,902	Closed	-$663K	–	362
2025 Q4	$663K	Buy	+2,902	New	+$661K	0.16%	191

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Farringdon Capital's ABBV Position: Q1 2026 in Review

Farringdon Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 2,902 shares — an estimated $663K sold.

Farringdon Capital first reported a position in ABBV in Q4 2025 and held it in 1 quarter. The position peaked at $663K in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Farringdon Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Farringdon Capital sold 2,902 AbbVie shares in Q1 2026, an estimated $663K.
Farringdon Capital first reported a position in AbbVie in Q4 2025 and held it in 1 quarter.
Farringdon Capital's AbbVie position peaked at $663K in Q4 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.